-
Mashup Score: 5
PURPOSEImmunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of the …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions - 5 month(s) ago
Molecular residual disease (MRD) tests have the potential to revolutionize neoadjuvant and adjuvant treatment. This article reviews current evidence for th
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
High-sensitivity #ctDNA tests can be used to detect radiologically occult disease or minimal residual disease post-surgery & identify high-risk patients. This review summarizes current evidence, w/ focus on genitourinary tumors. @KartikPatel___ https://t.co/d9TyXX3SmD https://t.co/EvIOQJx0hh
-
-
Mashup Score: 2David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA - OncoDaily - 5 month(s) ago
David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA / Cal Cancer Consortium, cancer, Cancer research, chemotherapy, ctDNA
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA - @drgandara https://t.co/lULxsYGjyU #ctDNA #Can…
-
-
Mashup Score: 5The Next Wave of Cancer Care: ctDNA’s Emerging Role - 6 month(s) ago
As the clinical utility of ctDNA continues to be assessed, it is becoming a valuable tool for various cancer types, including gastrointestinal cancers, blood cancers, and other solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
While the clinical utility of #ctDNA continues to be evaluated, it is emerging as a useful tool across various cancer types. Read more in this article which features @ADesaiMD, @pashtoonkasi, @marklewismd, @DrLaCasce! https://t.co/cW4ZPqismS
-
-
Mashup Score: 4
In this feature article, key opinion leaders look at the burgeoning use of ctDNA to dictate treatment approaches for patients with bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
“The presence or absence of #ctDNA after surgery is helping physicians and patients make informed decisions on whether there would actually be a benefit from the cytotoxic chemotherapy or not,” -@alantanmd of @VUMCDiscoveries. https://t.co/ikT0yz52w2
-
-
Mashup Score: 4NGS and ctDNA Considered in Advanced Breast Cancer After Progression - 8 month(s) ago
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ruth M. O'Regan, MD, discussed whether to order next-generation sequencing and/or #ctDNA testing for a patient with HR–positive breast cancer after progression. @WilmotCancer https://t.co/PIFIxlUJsj
-
-
Mashup Score: 4NGS and ctDNA Considered in Advanced Breast Cancer After Progression - 9 month(s) ago
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ruth M. O'Regan, MD, discussed whether to order next-generation sequencing and/or #ctDNA testing for a patient with HR–positive breast cancer after progression. @WilmotCancer https://t.co/PIFIxlUJsj
-
-
Mashup Score: 3NGS and ctDNA Considered in Advanced Breast Cancer After Progression - 9 month(s) ago
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ruth M. O'Regan, MD, discussed whether to order next-generation sequencing and/or #ctDNA testing for a patient with HR–positive breast cancer after progression. @WilmotCancer https://t.co/PIFIxlUJsj
-
-
Mashup Score: 1ctMoniTR Project - Friends of Cancer Research - 10 month(s) ago
ctDNA for Monitoring Treatment Response Project Quick Links Sign Up for Updates ctMoniTR Project One Pager Project Outcomes ctMoniTR Project Slides ASCO Annual Meeting Poster The ctDNA to Monitor Treatment Response (ctMoniTR) Project is a first of its kind partnership led by Friends of Cancer Research (Friends) to answer the important question: Do changes in…
Source: friendsofcancerresearch.orgCategories: General Medicine News, Onc News and JournalsTweet-
The ctMoniTR project is validating if blood biomarkers, such as #ctDNA can be used to easily determine if a drug is working. By getting this information quickly & in a less invasive way, physicians & patients will understand if the treatment is effective. https://t.co/DYH8eAXXww https://t.co/3vNUEeDwVk
-
-
Mashup Score: 27[Vídeo] EP37 - ctDNA in Colorectal Cancer - Beyond Early Detection - 10 month(s) ago
Listen to this episode from The Late Night Oncology Show on Spotify. [Episódio em Inglês] Para fechar o mês de conscientização dos tumores colorretais, recebemos Dr. Pashtoon Kasi, oncologista clínico com foco em tumores gastrointestinais, professor na Weill Cornell Medicine e autor do estudo BESPOKE CRC, para discutir aspectos relacionados a biópsia líquida em câncer colorretal, incluindo a importância na detecção precoce, determinação de tratamento adjuvante e monitoramento do tratamento no cenário metastático.
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Was a delight to be on the @LateNightOnc🎙️🇧🇷 in the company of some wonderful physicians & scientists discussing #ctDNA🧬🩸. 👇🏾Episode available on Spotify. 💡More now than ever it is important to understand the limitations & best use case/scenarios. https://t.co/vMpl6O6o1m https://t.co/iJi6kNzSAY https://t.co/wZSBT6Dvvn
-
Beyond #ctDNA MRD, what else can help stratify these patients? Intriguing that immunoscore within patients who are ctDNA➖ can further delineate groups👇🏽: 2yr DFS 🟢—— 💯% 🔵—— 90% 🔴—— 86% @JCO_ASCO https://t.co/oh6u0GDSbd The IDEA💡🇫🇷 initial ctDNA studies. @OncoAlert https://t.co/eCbmtKxWhw